C1S and cold agglutinin disease: Other complement-targeting agents that may find a role in the treatment of CAD are ANX005, a C1q inhibitor (143, 144), BIVV020, which targets C1s (145) (ClinicalTrials.gov, NCT04269551), and ARGX-117, which inhibits C2 (146).